There’s a growing body of evidence suggesting that the human microbiome, especially the gut microbiome, may be a source for potential biomarkers leading to therapeutic discoveries and potential diagnostics. But the range of success in different disease indications varies from very murky to much more pinpointed with a higher degree of consensus across studies.

We discuss it with Emily Hollister, Vice President of Diversigen.